Percheron Therapeutics Limited (ASX:PER)
0.0110
+0.0010 (10.00%)
May 30, 2025, 1:55 PM AEST
Percheron Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
Cash & Equivalents | 17.39 | 11.87 | 10.97 | 19.23 | 6.02 | 4.06 | Upgrade
|
Cash & Short-Term Investments | 17.39 | 11.87 | 10.97 | 19.23 | 6.02 | 4.06 | Upgrade
|
Cash Growth | 1.14% | 8.20% | -42.98% | 219.47% | 48.31% | 39.81% | Upgrade
|
Accounts Receivable | 0.34 | 0.08 | 0.03 | 0.03 | 0.01 | - | Upgrade
|
Other Receivables | - | 2.48 | 1.63 | 1.81 | 0.59 | 0.69 | Upgrade
|
Receivables | 0.34 | 2.57 | 1.66 | 1.84 | 0.6 | 0.69 | Upgrade
|
Prepaid Expenses | 0.1 | 0.04 | 0.07 | 0.61 | 0.08 | 0.21 | Upgrade
|
Other Current Assets | - | - | - | 0.53 | - | 0.26 | Upgrade
|
Total Current Assets | 17.83 | 14.47 | 12.69 | 22.22 | 6.7 | 5.21 | Upgrade
|
Property, Plant & Equipment | 0.09 | 0.06 | 0.15 | 0.22 | 0.3 | 0.14 | Upgrade
|
Total Assets | 17.92 | 14.53 | 12.84 | 22.44 | 7 | 5.35 | Upgrade
|
Accounts Payable | 2.29 | 3.73 | 1.02 | 0.33 | 0.16 | 0.11 | Upgrade
|
Accrued Expenses | 0.27 | 1.38 | 1.69 | 0.73 | 0.8 | 0.57 | Upgrade
|
Current Portion of Leases | 0.07 | 0.04 | 0.09 | 0.09 | 0.08 | 0.11 | Upgrade
|
Other Current Liabilities | - | - | 0 | 0 | 0 | 0 | Upgrade
|
Total Current Liabilities | 2.63 | 5.15 | 2.81 | 1.16 | 1.05 | 0.8 | Upgrade
|
Long-Term Leases | - | - | 0.05 | 0.13 | 0.23 | 0.02 | Upgrade
|
Other Long-Term Liabilities | - | 0.02 | 0.01 | 0 | 0 | - | Upgrade
|
Total Liabilities | 2.63 | 5.17 | 2.87 | 1.3 | 1.27 | 0.82 | Upgrade
|
Common Stock | 123.41 | 109.37 | 98.26 | 98.13 | 77.03 | 69.15 | Upgrade
|
Retained Earnings | -110.27 | -101.73 | -92.29 | -80.91 | -75.1 | -67.04 | Upgrade
|
Comprehensive Income & Other | 2.15 | 1.72 | 4 | 3.92 | 3.79 | 2.42 | Upgrade
|
Shareholders' Equity | 15.29 | 9.36 | 9.98 | 21.14 | 5.73 | 4.53 | Upgrade
|
Total Liabilities & Equity | 17.92 | 14.53 | 12.84 | 22.44 | 7 | 5.35 | Upgrade
|
Total Debt | 0.07 | 0.04 | 0.14 | 0.23 | 0.31 | 0.14 | Upgrade
|
Net Cash (Debt) | 17.32 | 11.83 | 10.83 | 19.01 | 5.71 | 3.92 | Upgrade
|
Net Cash Growth | 0.81% | 9.25% | -43.04% | 232.64% | 45.60% | 35.15% | Upgrade
|
Net Cash Per Share | 0.02 | 0.01 | 0.02 | 0.03 | 0.01 | 0.01 | Upgrade
|
Filing Date Shares Outstanding | 1,087 | 901.54 | 836.3 | 668.79 | 574.48 | 488.79 | Upgrade
|
Total Common Shares Outstanding | 1,087 | 901.54 | 669.31 | 668.79 | 574.48 | 488.79 | Upgrade
|
Working Capital | 15.2 | 9.32 | 9.88 | 21.06 | 5.65 | 4.42 | Upgrade
|
Book Value Per Share | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | 0.01 | Upgrade
|
Tangible Book Value | 15.29 | 9.36 | 9.98 | 21.14 | 5.73 | 4.53 | Upgrade
|
Tangible Book Value Per Share | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | 0.01 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.